Accueil   Diary - News   All news Adocia announces new BioChaperone program combining a basal insulin and GLP-1s

Adocia announces new BioChaperone program combining a basal insulin and GLP-1s

ADOCIA-HOMEAdocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, today announced the launch of a new program employing its proprietary BioChaperone® technology to develop combinations of insulin glargine (Lantus®, Sanofi) and GLP-1 receptor agonists (GLP-1s).

 

 


“We are very excited about these two new combinations, the first to incorporate GLP-1 agents with our BioChaperone technology” said Gérard Soula, Chairman and CEO...

 

Read the press release